dBET6 downregulates the expression of myelocytomatosis viral oncogene (Myc) in all cancer cell lines, has anti-tumor effects, and can also block cell resistance in most chronic myeloid leukemia lines, and is more effective than the first-generation BRD4-targeted drug dBET1 [66,67,68]. Here, BRD4 is linked to cancer.